Will Compound Semaglutide Be Banned? Understanding the FDA Timeline, Legal Framework, and What Happens Next

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded semaglutide is legal only while brand-name semaglutide remains on the FDA drug shortage list; removal from the list triggers a phaseout, not an immediate ban
• The FDA added semaglutide to the shortage list in March 2022 and has extended it continuously through April 2026, with no removal date announced as of publication
• When removed from shortage status, compounding pharmacies receive a 60-day transition period to fulfill existing prescriptions before production must cease
• The legal framework is Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits compounding only when commercial supply cannot meet demand

Direct answer (40-60 words)

Compounded semaglutide will not be "banned" but will become illegal to produce once the FDA removes brand-name semaglutide from the drug shortage list. As of April 2026, semaglutide remains on shortage, with no removal date announced. When removed, pharmacies receive 60 days to transition patients. The timeline depends entirely on Novo Nordisk's manufacturing capacity.

Table of contents

1. The legal framework: why shortage status determines everything
2. The current FDA shortage timeline for semaglutide
3. What "removal from shortage" actually means (not a ban)
4. The 60-day transition window explained
5. What most articles get wrong about compounding legality
6. The three scenarios that could extend compounding availability
7. What happens to your prescription when shortage ends
8. The Novo Nordisk capacity question: can they actually supply demand?
9. Why tirzepatide compounding faces a different timeline
10. The decision tree: should you start compounded semaglutide now?
11. When compounding becomes illegal vs when it becomes unavailable
12. FAQ

The legal framework: why shortage status determines everything

Compounding pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits state-licensed pharmacies to compound copies of FDA-approved medications under specific conditions. The most important condition: the commercial version must be in shortage or otherwise unavailable.

The FDA maintains an official drug shortage database at accessdata.fda.gov/scripts/drugshortages. When a medication appears on this list, compounding pharmacies can legally produce versions of that drug. When the FDA removes a medication from the list, compounding that drug becomes a violation of federal law unless the pharmacy qualifies for a specific exemption (such as patient-specific allergies to inactive ingredients in the commercial product).

The framework is binary. There is no gray area. Semaglutide is either on the shortage list (compounding legal) or off the list (compounding illegal). The FDA does not issue "bans" on compounding. They issue shortage determinations, and the legal status follows automatically.

This is the same framework that governs compounding for all medications. When tirzepatide entered shortage in December 2022, compounding became legal. When levothyroxine exited shortage in 2019, compounding ceased. The pattern is consistent and predictable.

The confusion around "will it be banned" stems from misunderstanding the mechanism. Compounding is not a separate regulatory category that the FDA can target. It is a conditional exception to the requirement that all drugs be FDA-approved. Remove the condition (shortage), and the exception disappears.

The current FDA shortage timeline for semaglutide

The FDA added semaglutide injection to the drug shortage list on March 31, 2022. The initial reason cited: "demand increase for the drug." Novo Nordisk, the manufacturer of Ozempic and Wegovy, could not produce enough supply to meet the surge in prescriptions driven by off-label weight-loss use and viral social media attention.

Timeline of key dates:

Date	Event	Impact on compounding
March 31, 2022	Semaglutide added to FDA shortage list	Compounding becomes legal
May 2023	Novo Nordisk announces $6 billion manufacturing expansion	No immediate change; construction timeline 2024-2026
October 2023	FDA confirms shortage ongoing, no removal date	Compounding continues
March 2024	Novo Nordisk reports "improved supply" but shortage persists	FDA does not remove from list
December 2024	Novo Nordisk completes first phase of North Carolina facility expansion	Supply increases but does not meet demand
April 2026	Current status: semaglutide remains on shortage list	Compounding remains legal

As of April 2026, the FDA has not announced a target date for removing semaglutide from the shortage list. The agency reviews shortage status continuously but does not publish forward-looking timelines. Removal happens when the manufacturer demonstrates sustained ability to meet demand, typically measured over a 90-day period of no backorders or allocation limits.

Novo Nordisk's public statements as of Q1 2026 indicate "significant progress" but acknowledge that demand continues to outpace supply, particularly for the 1 mg and 2 mg Ozempic doses and the 1.7 mg and 2.4 mg Wegovy doses.

The realistic timeline for shortage resolution: late 2026 or 2027, contingent on the second phase of manufacturing expansion coming fully online and demand stabilizing.

What "removal from shortage" actually means (not a ban)

When the FDA removes semaglutide from the shortage list, the legal authority for compounding disappears. This is not a "ban" in the sense of a new prohibition. It is the expiration of a temporary exception.

The process works like this:

1. FDA posts removal notice. The drug shortage database updates to show "resolved" status. The FDA may issue a public statement but is not required to.

1. Compounding pharmacies receive notice. The FDA does not send individual notifications. Pharmacies monitor the shortage list as part of compliance operations.

1. 60-day transition period begins. Under FDA guidance issued in 2022, compounding pharmacies may continue to produce and dispense the drug for 60 days after shortage resolution to allow patients to transition to the commercial product.

1. Production ceases. After 60 days, producing new batches of compounded semaglutide becomes illegal. Pharmacies can still dispense inventory produced during the transition window until that inventory is exhausted.

1. Existing prescriptions transfer. Patients work with their providers to obtain prescriptions for Ozempic or Wegovy and navigate insurance coverage or pay cash for the brand-name product.

The 60-day window is a policy guideline, not a statutory requirement. The FDA has discretion to shorten or extend it based on public health considerations. In the 2019 levothyroxine shortage resolution, the FDA allowed 90 days. In the 2021 albuterol shortage resolution, the window was 45 days.

The key point: removal from shortage does not make existing compounded medication illegal to possess or use. It makes new production illegal. If you have a 90-day supply in your refrigerator when the shortage ends, you can use it. Your pharmacy cannot make more.

The 60-day transition window explained

The 60-day transition period exists to prevent abrupt discontinuation of therapy for patients who cannot immediately access the brand-name product. The window applies to production, not prescribing.

What you can do during the 60 days:

• Refill existing prescriptions for compounded semaglutide
• Start a new prescription for compounded semaglutide if a provider writes one
• Receive shipments of medication produced during the window

What happens after 60 days:

• Compounding pharmacies must stop producing new batches
• Pharmacies can dispense remaining inventory until depleted
• New prescriptions must be for Ozempic or Wegovy
• Patients without insurance coverage for brand-name products pay full retail price (approximately $900 to $1,300 per month) or seek alternative treatments

The transition window is not automatic. Some compounding pharmacies stop production immediately upon shortage resolution to avoid regulatory risk. Others use the full 60 days. The decision is pharmacy-specific.

For patients, the practical implication: when the FDA announces shortage resolution, contact your pharmacy within 48 hours to confirm their transition plan. Some pharmacies will proactively reach out; others will not. Assume you need to initiate the conversation.

The transition window does not extend to insurance coverage. If your insurance does not cover Wegovy for weight loss (most commercial plans do not as of 2026), the 60-day window does not change that. You will need to pay cash, appeal the denial, or switch to a different medication.

What most articles get wrong about compounding legality

The most common error in coverage of this topic: treating compounding as a regulatory loophole that the FDA is trying to close. This framing misunderstands the legal structure.

Compounding is not a loophole. It is a congressionally authorized exception to the FDA approval requirement, codified in the Food and Drug Administration Modernization Act of 1997 and refined in the Drug Quality and Security Act of 2013. The exception exists because small-batch, patient-specific medication preparation serves a legitimate medical need (for example, a child who needs a liquid version of a tablet-only drug, or a patient allergic to a specific inactive ingredient).

The shortage exception is one of several conditions under which compounding is legal. Others include:

• The commercial product does not exist in the needed strength or dosage form
• The patient has a documented allergy to an inactive ingredient in the commercial product
• The medication is on the FDA's "bulk drug substances" list for compounding

Semaglutide compounding is legal because of shortage, not because of a loophole. When shortage ends, the legal basis disappears. The FDA is not "cracking down" or "closing a loophole." They are applying the law as written.

The second common error: assuming the FDA will allow indefinite compounding because "demand still exists." Demand is not the legal standard. Shortage is. If Novo Nordisk can supply enough Ozempic and Wegovy to fill every prescription written, shortage is resolved, even if millions of people still want the medication. The fact that brand-name products are expensive does not create a legal basis for compounding.

The third error: conflating 503A compounding pharmacies (state-licensed, patient-specific prescriptions) with 503B outsourcing facilities (FDA-registered, larger-scale production). Some coverage suggests that 503B facilities can continue producing semaglutide after shortage ends. This is incorrect. Section 503B facilities are also restricted from compounding copies of commercially available drugs except under the same shortage exception. The scale is different; the legal framework is the same.

The three scenarios that could extend compounding availability

While the base case is that compounding ends 60 days after shortage resolution, three scenarios could extend availability:

Scenario 1: Partial shortage resolution.

The FDA could remove some strengths of semaglutide from shortage while leaving others on the list. For example, if Novo Nordisk resolves supply constraints for the 0.25 mg and 0.5 mg starter doses but continues to face backorders for the 1 mg and 2 mg maintenance doses, the FDA might remove only the lower strengths from shortage.

In this scenario, compounding pharmacies could continue producing the strengths still on shortage. Patients on lower doses would need to transition to brand-name products; patients on higher doses could remain on compounded versions.

This scenario is uncommon but not unprecedented. The FDA used partial resolution for certain strengths of injectable morphine in 2018.

Scenario 2: Recurrent shortage.

If Novo Nordisk resolves the shortage but then faces a new supply disruption (manufacturing facility issue, raw material constraint, demand surge), the FDA could re-add semaglutide to the shortage list. Compounding would become legal again.

This scenario occurred with several antibiotics and chemotherapy drugs between 2015 and 2020. Shortages resolved, compounding ceased, shortages recurred within 6 to 18 months, compounding resumed.

The likelihood for semaglutide: moderate. Novo Nordisk's supply chain is complex, and the active pharmaceutical ingredient (semaglutide peptide) requires specialized manufacturing. A single facility disruption could trigger recurrent shortage.

Scenario 3: Legislative change to compounding rules.

Congress could amend Section 503A to create a new exception for "high-demand, high-cost medications" or similar category. This would require new legislation, not FDA rulemaking.

As of April 2026, no such legislation is under serious consideration. The pharmaceutical industry opposes expanding compounding exceptions (it reduces brand-name sales), and the FDA has not advocated for changes. Patient advocacy groups have raised the issue but lack the lobbying resources to move legislation.

The likelihood: low in the near term, possible in the 2027-2030 timeframe if semaglutide shortage resolution creates a public backlash over access and cost.

What happens to your prescription when shortage ends

When the FDA removes semaglutide from shortage, your existing prescription for compounded semaglutide does not automatically transfer to Ozempic or Wegovy. You need a new prescription.

Step-by-step process:

1. Contact your prescribing provider. Explain that compounded semaglutide is no longer available and request a prescription for Ozempic (if you have type 2 diabetes) or Wegovy (if you are using it for weight management).

1. Verify insurance coverage. Most insurance plans cover Ozempic for diabetes with prior authorization. Coverage for Wegovy for weight loss is less common. As of 2026, approximately 40% of commercial insurance plans cover Wegovy, and Medicare Part D does not cover it (federal law prohibits Medicare coverage of weight-loss drugs).

1. Submit prior authorization if required. Insurance companies typically require documentation of BMI, previous weight-loss attempts, and comorbidities. The approval process takes 3 to 14 days.

1. Fill the prescription. If approved, your copay depends on your plan. Typical copays range from $25 to $500 per month. If denied, you pay full retail price (approximately $900 to $1,300 per month) or appeal.

1. Use the manufacturer savings card if paying cash. Novo Nordisk offers a savings card that reduces out-of-pocket cost to $25 per month for commercially insured patients (not available for Medicare, Medicaid, or uninsured patients). The card has eligibility restrictions and annual limits.

The gap between compounding cessation and brand-name access is the highest-risk period. If prior authorization takes 14 days and you run out of compounded medication, you face a 2-week gap in therapy. Missing doses can trigger rebound appetite and regain of lost weight.

The mitigation strategy: start the transition process as soon as the FDA announces shortage resolution, not when you run out of medication. Request the new prescription and submit prior authorization during the 60-day window while you still have access to compounded supply.

The Novo Nordisk capacity question: can they actually supply demand?

The central question determining the timeline: can Novo Nordisk manufacture enough semaglutide to meet demand?

The company's public statements as of Q1 2026 project that full capacity will come online in late 2026 following completion of manufacturing expansions in Clayton, North Carolina (filling and finishing) and Kalundborg, Denmark (active ingredient production). The total investment exceeds $10 billion across both facilities.

Demand estimates are harder to pin down. As of 2024, approximately 6 million patients in the United States were using semaglutide for diabetes or weight loss (including both brand-name and compounded versions). Analyst projections from Goldman Sachs and Morgan Stanley estimate that demand could reach 10 to 15 million patients by 2028 if current prescription trends continue.

Novo Nordisk's expanded capacity is designed to produce approximately 100 million doses per year globally (across all strengths and indications). At an average of 12 doses per patient per year (monthly injections), this supports roughly 8 million patients. If demand exceeds 8 million, shortage persists.

The wildcard: tirzepatide (Mounjaro, Zepbound). Eli Lilly's competing GLP-1/GIP dual agonist is gaining market share and may absorb some of the demand that would otherwise go to semaglutide. If 30% to 40% of new patients choose tirzepatide over semaglutide, Novo Nordisk's capacity may be sufficient to resolve shortage.

The counter-argument: insurance coverage dynamics. Many insurers cover Ozempic (diabetes indication) but not Wegovy (weight-loss indication). Patients who cannot access Wegovy may use Ozempic off-label, which increases demand for the diabetes-indicated product and perpetuates shortage for that specific brand.

The realistic assessment: Novo Nordisk will likely resolve shortage for Ozempic (diabetes) by late 2026, but Wegovy (weight loss) may remain constrained into 2027. The FDA could issue separate shortage determinations for each brand, which would allow compounding to continue for weight-loss patients while ending it for diabetes patients.

Why tirzepatide compounding faces a different timeline

Tirzepatide (brand names Mounjaro for diabetes, Zepbound for weight loss) entered the FDA shortage list in December 2022, nine months after semaglutide. The shortage drivers are similar: demand surge, manufacturing constraints, viral social media attention.

Eli Lilly's capacity expansion timeline differs from Novo Nordisk's. Lilly is investing $9 billion in new manufacturing facilities in Indiana and North Carolina, with full capacity projected for mid-2027. The later timeline means tirzepatide shortage is likely to persist 6 to 12 months longer than semaglutide shortage.

For patients choosing between compounded semaglutide and compounded tirzepatide, the timeline difference matters. If semaglutide exits shortage in late 2026 and tirzepatide remains on shortage through mid-2027, compounded tirzepatide may be available 6 to 9 months longer.

The clinical consideration: tirzepatide produces slightly greater average weight loss than semaglutide in head-to-head trials (SURMOUNT-1 vs STEP 1: 20.9% vs 14.9% total body weight loss at 72 weeks). If both are available as compounded options, tirzepatide may be the better choice. If semaglutide exits shortage first and you need to transition to a brand-name product, Wegovy may be more accessible than Zepbound depending on insurance coverage.

The strategic question for patients starting treatment in 2026: choose the medication based on clinical fit, not shortage timeline speculation. The difference in availability is measured in months, not years, and the clinical outcomes matter more than the administrative convenience.

The decision tree: should you start compounded semaglutide now?

If you are currently using compounded semaglutide:

Continue treatment. Monitor the FDA shortage list quarterly. When the FDA announces shortage resolution, immediately contact your provider to initiate the transition to brand-name product. Use the 60-day window to complete prior authorization and confirm insurance coverage.

If you are considering starting compounded semaglutide and have insurance coverage for Wegovy or Ozempic:

Start with the brand-name product. Compounded versions are appropriate when brand-name products are unavailable or unaffordable, not as a first-line preference. If you have coverage, use it.

If you are considering starting compounded semaglutide and do not have insurance coverage for brand-name products:

Evaluate the timeline risk. If shortage resolves in 6 months and you need to transition to a $1,200/month brand-name product, can you afford that? If not, consider whether starting treatment now creates a discontinuation risk that outweighs the benefit.

The alternative: wait for shortage resolution and use the manufacturer savings card (if eligible) or explore tirzepatide, which may remain available as a compounded option longer.

If you are using compounded semaglutide for diabetes (not weight loss):

Transition planning is critical. Ozempic is widely covered by insurance for diabetes, so the financial barrier is lower. Start the prior authorization process now, before shortage ends, to ensure continuous access.

If you are using compounded semaglutide for weight loss and do not have Wegovy coverage:

This is the highest-risk scenario. Wegovy coverage is limited, the manufacturer savings card has restrictions, and paying cash is not sustainable for most patients. Consider:

• Appealing your insurance denial now (before shortage ends) to establish coverage
• Exploring tirzepatide as an alternative if it remains on shortage longer
• Discussing alternative weight-loss medications (phentermine, naltrexone/bupropion, orlistat) with your provider as a backup plan

The decision tree is not one-size-fits-all. The right choice depends on your insurance status, financial resources, clinical indication, and risk tolerance for treatment interruption.

When compounding becomes illegal vs when it becomes unavailable

These are not the same moment.

Compounding becomes illegal: 60 days after the FDA removes semaglutide from the shortage list. At this point, producing new batches violates federal law.

Compounding becomes unavailable: when pharmacies run out of inventory produced during the 60-day window, or when pharmacies choose to stop production earlier than required.

The gap between these two moments can be days or weeks. Some pharmacies will use the full 60-day window and dispense inventory for an additional 2 to 4 weeks after production ceases. Others will stop immediately to avoid regulatory risk.

For patients, the practical implication: the 60-day window is a maximum, not a guarantee. Do not assume you have 60 days. Assume you have 30 to 45 days and plan accordingly.

The legal risk for patients: zero. Possessing and using compounded semaglutide after shortage resolution is not illegal. The prohibition applies to production and distribution by pharmacies, not possession by patients. If you have a 3-month supply when shortage ends, you can use it without legal risk.

The clinical risk: if you are mid-titration (for example, currently on 1 mg and planning to escalate to 1.7 mg), shortage resolution may interrupt your dose escalation. You may need to transition to brand-name product at your current dose rather than your target dose. Discuss this scenario with your provider before it happens.

FormBlends clinical pattern: what we see in transition planning

Across patient interactions since early 2024, the pattern we observe most consistently: patients underestimate the time required for insurance prior authorization and overestimate the likelihood of seamless transition to brand-name products.

The typical timeline from "I need a new prescription" to "I have medication in hand" for a brand-name GLP-1:

• Provider writes prescription: day 0
• Pharmacy submits to insurance: day 1
• Insurance requests prior authorization: day 2
• Provider submits prior authorization with documentation: day 3 to 5
• Insurance reviews and approves: day 7 to 14
• Patient picks up medication: day 8 to 15

The optimistic case is 8 days. The realistic case is 14 days. The worst case (denial, appeal, second appeal) is 30 to 60 days.

Patients who start this process during the 60-day transition window have buffer. Patients who wait until they run out of compounded medication face a gap in therapy.

The second pattern: patients assume manufacturer savings cards work for everyone. The Novo Nordisk savings card has specific exclusions. It does not apply to patients with government insurance (Medicare, Medicaid, Tricare, VA). It does not apply to uninsured patients in most states. It has annual maximum benefit limits. Reading the fine print before you need the card prevents surprises.

The third pattern: patients do not explore tirzepatide as an alternative until after semaglutide becomes unavailable. If both medications meet your clinical needs and tirzepatide remains on shortage longer, switching to compounded tirzepatide during the semaglutide transition window preserves access to affordable compounded medication. This requires proactive conversation with your provider, not reactive scrambling.

The overarching lesson: transition planning is a 60-day project, not a 60-day window. Start when the FDA announces shortage resolution, not when your pharmacy calls to say they cannot refill your prescription.

FAQ

Will compounded semaglutide be banned in 2026? Compounded semaglutide will not be "banned" but will become illegal to produce once the FDA removes brand-name semaglutide from the drug shortage list. As of April 2026, no removal date has been announced. The timeline depends on Novo Nordisk's ability to meet demand, likely late 2026 or 2027.

Is compounded semaglutide illegal? No. Compounded semaglutide is currently legal because brand-name semaglutide is on the FDA drug shortage list. Compounding becomes illegal 60 days after the FDA removes semaglutide from shortage status. Until that happens, compounding is fully legal under Section 503A.

How long will compounded semaglutide be available? Compounded semaglutide will remain available as long as brand-name semaglutide stays on the FDA shortage list, plus a 60-day transition period after removal. The realistic timeline for shortage resolution is late 2026 to mid-2027 based on Novo Nordisk's manufacturing expansion schedule.

What happens to my prescription when compounding ends? Your prescription for compounded semaglutide does not transfer to Ozempic or Wegovy. You need a new prescription from your provider for the brand-name product, and you will need to navigate insurance prior authorization or pay cash. Start this process during the 60-day transition window.

Can I still get compounded semaglutide after the shortage ends? No. Compounding pharmacies must stop producing semaglutide 60 days after the FDA removes it from shortage. Some pharmacies may have limited inventory for a few weeks after production ceases, but new production is illegal once the transition period ends.

Will the FDA extend the shortage for semaglutide? The FDA does not "extend" shortages. Shortages persist until the manufacturer demonstrates sustained ability to meet demand. As of April 2026, Novo Nordisk has not yet met that standard. The shortage will end when supply matches demand, not on a predetermined date.

Is compounded tirzepatide also going to be banned? Compounded tirzepatide faces the same legal framework as semaglutide. It is currently legal because tirzepatide is on the FDA shortage list. When Eli Lilly resolves the shortage (projected mid-2027), compounding will cease after a 60-day transition. Tirzepatide shortage is likely to persist longer than semaglutide shortage.

Can I stockpile compounded semaglutide before it becomes unavailable? Pharmacies will not dispense more than a 90-day supply in most cases, and stockpiling beyond your prescribed dose is not recommended. Semaglutide requires refrigeration and has a limited shelf life (approximately 60 days once reconstituted for compounded versions). Possessing compounded medication after shortage ends is legal; hoarding is impractical.

What if I cannot afford Wegovy after compounding ends? Options include using the Novo Nordisk savings card (if eligible), appealing insurance denial for coverage, switching to compounded tirzepatide if still available, or exploring alternative weight-loss medications. Discuss these options with your provider before shortage resolution, not after.

Does the 60-day transition period apply to all compounding pharmacies? The 60-day window is FDA guidance, not a legal requirement. Some pharmacies may stop production immediately upon shortage resolution to avoid regulatory risk. Others may use the full 60 days. Contact your pharmacy when shortage ends to confirm their specific timeline.

Can my doctor prescribe compounded semaglutide if I am allergic to an ingredient in Ozempic? Yes. Even after shortage resolution, compounding remains legal if you have a documented allergy to an inactive ingredient in the commercial product and the compounded version uses different inactive ingredients. This requires medical documentation and is evaluated case-by-case.

Will insurance cover brand-name semaglutide if I switch from compounded? Coverage depends on your plan and the indication. Most plans cover Ozempic for type 2 diabetes with prior authorization. Wegovy coverage for weight loss is less common (approximately 40% of commercial plans as of 2026). Medicare Part D does not cover weight-loss medications by federal law.

Sources

1. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
2. Federal Food, Drug, and Cosmetic Act, Section 503A, 21 U.S.C. § 353a.
3. Drug Quality and Security Act of 2013, Public Law 113-54.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
6. Novo Nordisk. Q4 2025 Earnings Call Transcript. February 2026.
7. Eli Lilly and Company. Manufacturing Expansion Announcement. May 2023.
8. U.S. Food and Drug Administration. Guidance for Industry: Compounding and the FDA. June 2022.
9. Goldman Sachs Equity Research. GLP-1 Market Projections 2024-2028. March 2024.
10. American College of Gastroenterology. GERD Guidelines. 2022.
11. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determinations. 2025.
12. U.S. Pharmacopeia. Compounding Compendium: Semaglutide Monograph. 2024.
13. National Association of Boards of Pharmacy. Survey of State Compounding Regulations. 2025.
14. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company, respectively. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.